Federal Trade Commission Cracks Down On Unproven COVID-19 Treatment
The Federal Trade Commission issued warning letters to several companies that marketed an unproven drug to treat COVID-19. Sales of the non-approved drug, thymosin alpha-1, were first reported by NPR.
As the U.S. death toll from the coronavirus passed , and public health officials scrambled to respond to increasing infections around the country, the Federal Trade Commission announced additional steps Thursday to crack down on unproven treatments for COVID-19 and companies that might prey on Americans'
